Ra Medical Systems, Inc. (RMED)
Stock Price:
$0.430 USD
-0.015 (-3.37%)
Updated Jul 9, 2020 9:48 AM EDT - Market open
Key Info
| Market Cap |
14.89M |
| Revenue (ttm) |
6.83M |
| Net Income (ttm) |
-49.98M |
| Shares Out |
34.62M |
| EPS (ttm) |
-3.73 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 9, 2020 |
| Last Price |
$0.430 |
| Previous Close |
$0.445 |
| Change ($) |
-0.015 |
| Change (%) |
-3.37% |
| Day's Open |
0.439 |
| Day's Range |
0.430 - 0.443 |
| Day's Volume |
423,303 |
| 52-Week Range |
0.345 - 3.630 |
More Stats
| Market Cap |
14.89M |
| Enterprise Value |
n/a |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
34.62M |
| Float |
9.66M |
| EPS (basic) |
-3.72 |
| EPS (diluted) |
-3.73 |
| FCF / Share |
-2.28 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.16M |
| Short Ratio |
0.27 |
| Short % of Float |
7.33% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
2.18 |
| PB Ratio |
0.62 |
| Revenue |
6.83M |
| Operating Income |
-50.57M |
| Net Income |
-49.98M |
| Free Cash Flow |
-31.40M |
| Net Cash |
20.10M |
| Net Cash / Share |
0.58 |
| Gross Margin |
-24.19% |
| Operating Margin |
-740.89% |
| Profit Margin |
-732.40% |
| FCF Margin |
-460.12% |
| ROA |
-59.87% |
| ROE |
-115.88% |
| ROIC |
-159.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
1 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$1.50*
(248.84% upside)
Low
1.00
Current: 0.430
High
2.00
Target: 1.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 7.20 | 6.26 | 5.87 | 5.98 |
| Revenue Growth | 15.06% | 6.59% | -1.77% | - |
| Gross Profit | -1.65 | 2.05 | 1.71 | 2.84 |
| Operating Income | -57.73 | -31.16 | -17.76 | -4.20 |
| Net Income | -56.96 | -30.83 | -17.77 | -4.20 |
| Shares Outstanding | 13.15 | 9.23 | 7.55 | 6.95 |
| Earnings Per Share | -4.33 | -3.34 | -2.35 | -0.60 |
| Operating Cash Flow | -33.17 | -18.51 | -5.52 | -1.89 |
| Capital Expenditures | -0.27 | -0.58 | -0.55 | -0.21 |
| Free Cash Flow | -33.44 | -19.09 | -6.07 | -2.10 |
| Cash & Equivalents | 30.58 | 64.32 | 8.24 | 3.92 |
| Total Debt | 3.50 | 0.85 | 0.06 | 0.11 |
| Net Cash / Debt | 27.08 | 63.47 | 8.17 | 3.81 |
| Assets | 44.08 | 74.04 | 11.27 | 5.84 |
| Liabilities | 10.93 | 7.33 | 18.88 | 6.22 |
| Book Value | 33.15 | 66.71 | -7.62 | -0.38 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Ra Medical Systems, Inc. |
| Country |
United States |
| Employees |
86 |
| CEO |
Jonathan Will McGuire |
Stock Information
| Ticker Symbol |
RMED |
| Stock Exchange |
New York Stock Exchange |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NYSE: RMED |
| IPO Date |
August 30, 2018 |
Description
Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for the treatment of vascular and dermatological diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and disposable catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. It also provides Pharos, an excimer laser device that emits highly concentrated ultraviolet light used in the treatment of dermatological skin disorders. The company sells its products primarily through its direct sales force in the United States. Ra Medical Systems, Inc. was founded in 2002 and is headquartered in Carlsbad, California.